Using this modified LFIA with two combinations of biotinylated primary antibodies and nano-gold conjugated antibodies, we were able to establish standard calibration curves from huMETCAM/MUC18 recombinant proteins and used these curves to determine the serum METCAM/MUC18 concentrations in normal individuals, BPH patients, patients with PIN, prostate cancer patients with various Gleason scores, and treated prostate cancer patients. This evidence concerns the gene MCAM and prostate carcinoma.